Yat Sun Or
2016
In 2016, Yat Sun Or earned a total compensation of $1.3M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 22% decrease compared to previous year.
Compensation breakdown
| Bonus | $114,633 |
|---|---|
| Non-Equity Incentive Plan | $48,078 |
| Option Awards | $654,806 |
| Salary | $386,069 |
| Stock Awards | $122,428 |
| Other | $15,857 |
| Total | $1,341,871 |
Or received $654.8K in option awards, accounting for 49% of the total pay in 2016.
Or also received $114.6K in bonus, $48.1K in non-equity incentive plan, $386.1K in salary, $122.4K in stock awards and $15.9K in other compensation.
Rankings
In 2016, Yat Sun Or's compensation ranked 6,797th out of 14,075 executives tracked by ExecPay. In other words, Or earned more than 51.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,797 out of 14,075 | 52nd |
Division Manufacturing | 2,537 out of 5,489 | 54th |
Major group Chemicals And Allied Products | 826 out of 1,895 | 56th |
Industry group Drugs | 635 out of 1,538 | 59th |
Industry Pharmaceutical Preparations | 502 out of 1,176 | 57th |
Source: SEC filing on January 19, 2018.
Or's colleagues
We found four more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2016.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019